Stephen From

Part of Kiora Pharmaceuticals, Inc., EyeGate Pharma SAS is a clinical-stage specialty pharmaceutical company based in Paris, France. EyeGate's products include pp-001, a next-generation, non-steroidal, immuno-modulatory and small molecule inhibitor of dihydroorotate dehydrogenase (“dhodh”) with picomolar potency and a validated immune modulating mechanism designed to overcome the off-target side effects and safety issues associated with dhodh inhibitors. The French company is also developing ocular bandage gel (“ obg ”), a modified form of the natural polymer hyaluronic acid, designed to protect the ocular surface to permit re-epithelialization of the cornea and improve ocular surface integrity. OBG, with unique properties that help hydrate and protect the ocular surface, is in clinical evaluation for patients undergoing photorefractive keratectomy (“prk”) surgery for corneal wound repair after refractive surgery and patients with persistent corneal epithelial defects. Founded in 1998, the company develops and commercializes products for treating ophthalmic diseases.

Aruna Bio, Inc. manufactures and provides neural stem cells. Its products include neuronet pure human neurons screening kit, neuronet pure human neurons discovery kit, co-culture kit hastropro-neuronet, hastropro human astrocytes kit and motor neurons GFP+htscreening kit. The company was founded by James Stice and Steven L. Stice in 2003 and is headquartered in Athens, GA.

Headquartered in Charlotte, North Carolina, Banc of America Securities (BAS) is the investment banking subsidiary of Bank of America Corp (NYSE: BAC). The firm provides both the domestic and international equity and investment banking markets, and pursues a strategy pioneered by Citigroup that combines corporate lending with investment banking advice and services. They provide high-yield debt underwriting and leveraged finance, in addition to industry coverage groups such as healthcare, media and telecom, financial institutions, real estate and gaming. BAS also does a significant amount of work for Financial Sponsors, or private equity firms, often financing leveraged transactions. Following the strategy of Goldman Sachs, the firm lacks a standalone mergers and acquisitions department, instead employing mergers and acquisitions senior bankers throughout the industry coverage groups. The firm is registered as a broker/dealer with the SEC, is a member of the NYSE, and the NASD. The use of Banc in the BAS's name is indicative of the fact that the company is not a bank, and their deposits and other holdings are not insured by the FDIC.